Preoperative prediction of KRAS mutation status in colorectal cancer using a CT-based radiomics nomogram

利用基于CT的放射组学列线图进行结直肠癌KRAS突变状态的术前预测

阅读:2

Abstract

OBJECTIVE: This study aimed to develop a model to predict KRAS mutations in colorectal cancer according to radiomic signatures based on CT and clinical risk factors. METHODS: This retrospective study included 172 patients with colorectal cancer. All patients were randomized at a 7:3 ratio into a training cohort (n = 121, 38.8% positive for KRAS mutation) and a validation cohort (n = 51, 39.2% positive for KRAS mutation). Radiomics features were extracted from single-slice and full-volume regions of interest on the portal-venous CT images. The least absolute shrinkage and selection operator (LASSO) algorithm was adopted to construct a radiomics signature, and logistic regression was applied to select the significant variables to develop the clinical-radiomics model. The predictive performance was evaluated by receiver operating characteristic curve (ROC) analysis, calibration curve analysis, and decision curve analysis (DCA). RESULTS: 1018 radiomics features were extracted from single-slice and full-volume ROIs. Eight features were retained to construct 2D (two-dimensional, 2D) radiomics model. Similarly, eight features were retained to construct 3D (three-dimensional, 3D) radiomics model. The area under the curve (AUC) values of the test cohort were 0.75 and 0.84, respectively. Delong test showed that the integrated nomogram (AUC = 0.92 in the test cohort) had better clinical predictive efficiency than 2D radiomics (p-value < 0.05) model and 3D radiomics model (p-value < 0.05). CONCLUSION: The 2D and 3D radiomics models can both predict KRAS mutations. And, the integrated nomogram can be better applied to predict KRAS mutation status in colorectal cancer. ADVANCES IN KNOWLEDGE: CT-based radiomics showed satisfactory diagnostic significance for the KRAS status in colorectal cancer, the clinical-combined model may be applied in the individual pre-operative prediction of KRAS mutation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。